Table 4.
(A) Five-year overall survival (%) for patients with right-sided colon cancer, 2006–2015 (95% CI 1). (B) Five-year overall survival (%) for patients with left-sided colon cancer, 2006–2015 (95% CI 1). (C) Five-year overall survival (%) for patients with rectal cancer, 2006–2015 (95% CI 1).
| Age Group | <75 Years Old | 75–79 Years Old | 80–84 Years Old | 85–89 Years Old | ≥90 Years Old |
|---|---|---|---|---|---|
| A | |||||
| FCR 2 0 | 70.1 (65.6–74.6) | 51.8 (43.8–59.8) | 43.4 (36.0–50.8) | 24.1 (16.5–31.7) | 16.8 (7.2–26.4) |
| FCR 1 | 87.4 (84.7–90.1) | 73.3 (67.2–79.4) | 55.4 (48.5–62.3) | 41.0 (32.0–50.0) | 18.9 (4.2–33.6) |
| FCR 2 | 57.7 (53.6–61.8) | 49.9 (42.3–57.5) | 37.3 (29.3–45.3) | 37.5 (27.5–47.5) | 20.9 (6.6–35.2) |
| FCR 3 | 47.2 (43.9–50.5) | 39.3 (34.3–44.4) | 29.7 (24.8–34.6) | 23.2 (17.1–29.3) | 8.5 (2.0–15.0) |
| FCR 4 | 47.6 (40.7–54.5) | 33.9 (20.8–47.0) | 27.5 (16.1–38.9) | 24.1 (13.3–34.9) | 7.9 (0.0–18.3) |
| FCR 5 | 79.9 (76.2–83.6) | 64.2 (55.6–72.8) | 59.2 (51.2–67.2) | 44.0 (32.8–55.2) | 17.9 (5.2–30.6) |
| FCR 6 | 12.2 (8.9–15.5) | 1.6 (0.0–4.7) | 5.6 (0.3–10.9) | 0.0 | 0.0 |
| All patients | 58.8 (57.2–60.4) | 49.2 (46.3–52.1) | 39.9 (37.2–42.6) | 29.1 (25.8–32.4) | 13.1 (8.8–17.4) |
| B | |||||
| FCR 2 0 | 67.4 (62.5–72.3) | 40.2 (30.0–50.4) | 44.8 (36.2–53.4) | 17.4 (9.2–25.6) | 0.0 |
| FCR 1 | 89.7 (87.2–92.2) | 73.4 (66.3–80.5) | 51.7 (42.7–60.7) | 45.1 (32.6–57.6) | 32.0 (12.0–52.0) |
| FCR 2 | 68.2 (64.1–72.3) | 53.0 (43.6–62.4) | 37.8 (27.4–48.2) | 15.5 (2.4–28.6) | 11.8 (0.0–31.0) |
| FCR 3 | 43.9 (40.4–47.4) | 36.4 (30.3–42.5) | 27.0 (20.5–33.5) | 13.4 (7.3–19.5) | 9.7 (0.0–19.9) |
| FCR 4 | 51.7 (43.5–59.9) | 33.5 (11.9–55.1) | 29.6 (14.1–45.1) | 21.4 (6.7–36.1) | 0.0 |
| FCR 5 | 81.9 (78.6–85.2) | 60.4 (50.8–70.0) | 47.0 (35.0–59.0) | 38.2 (24.9–51.5) | 13.4 (0.0–35.2) |
| FCR 6 | 18.5 (14.2–22.8) | 7.0 (0.5–13.5) | 0.0 | 0.0 | 7.7 (0.0–22.2) |
| All patients | 62.2 (60.6–63.8) | 47.6 (44.3–50.9) | 36.6 (32.9–40.3) | 22.5 (18.4–26.6) | 10.6 (5.1–16.1) |
| C | |||||
| FCR 2 0 | 67.3 (64.0–70.6) | 38.4 (31.5–45.3) | 27.6 (20.9–34.3) | 16.4 (10.5–22.3) | 1.9 (0.0–4.4) |
| FCR 1 | 89.1 (87.3–90.9) | 70.3 (65.0–75.6) | 55.9 (49.0–62.8) | 32.0 (23.6–40.4) | 7.5 (0.0–17.1) |
| FCR 2 | 70.1 (67.0–73.2) | 54.1 (45.9–62.3) | 35.9 (27.1–44.7) | 34.5 (22.5–46.5) | 0.0 |
| FCR 3 | 44.3 (41.4–47.2) | 35.4 (29.9–40.9) | 25.8 (20.5–31.1) | 15.2 (8.9–21.5) | 3.3 (0.0–9.8) |
| FCR 4 | 55.4 (48.9–61.9) | 45.5 (33.5–57.5) | 40.7 (26.6–54.8) | 9.0 (0.0–23.3) | 5.0 (0.0–14.6) |
| FCR 5 | 77.2 (74.1–80.3) | 55.0 (45.6–64.4) | 47.6 (37.0–58.2) | 43.4 (28.7–58.1) | 28.8 (2.7–54.9) |
| FCR 6 | 19.7 (16.2–23.2) | 4.6 (0.0–9.5) | 6.0 (0.5–11.5) | 0.0 | 0.0 |
| All patients | 64.3 (63.1–65.5) | 46.7 (44.0–49.4) | 34.7 (31.6–37.8) | 22.5 (19.0–26.0) | 5.0 (1.9–8.1) |
1 CI, confidence interval. 2 FCR, Finnish Cancer Registry classes: 0, unknown; 1, localized; 2, non-localized, regional lymph node metastasis only; 3, metastasized further than to regional lymph nodes or invading adjacent tissues; 4, non-localized, no information on extent; 5, locally advanced, tumor invasion to adjacent tissues; and 6, non-localized, including distant lymph node metastasis.